Abstract
Background
The aim of this study was to determine the efficacy and safety of 5% topical imiquimod, and the long-term results following its use, in the treatment of nodular basal cell carcinoma (BCC) of the eyelid.
Methods
Imiquimod cream (5%) was applied topically to five individuals affected by nodular BCC of the eyelid. The patients were followed up during the 6 weeks of treatment and for another 3 years after treatment. Local side effects and evidence of tumour regression or recurrence were noted.
Results
Complete clinical clearance of the tumour was obtained in four patients, with no response in the fifth patient. Therapy was typically accompanied by significant discomfort due to local side effects, which disappeared following completion of the treatment. None of these patients showed any local recurrence after 3 years.
Conclusions
Topical imiquimod applied in the form of a 5% cream proved to be a safe, efficacious and sustainable treatment option for nodular BCC of the eyelid in our selected cases.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M (2004) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50:722733
Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrandiz C, Garcia Diez A, Tebbs V, McRae S (2005) Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol 152:939–947
Huber A, Huber JD, Skinner RB Jr, Kuwahara RT, Haque R, Amonette RA (2004) Topical imiquimod treatment for nodular basal cell carcinomas: an open-label series. Dermatol Surg 30:429–430
Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, Andres K, Amies M, Owens M (2002) Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 138:1165–1171
Blasi MA, Giammaria D, Balestrazzi E (2005) Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am J Ophthalmol 140:1136–1139
Sauder DN (2004) Mechanism of action and emerging role of immune response modifier therapy in dermatologic conditions. J Cutan Med Surg 8[Suppl 3]:3–12
Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R (2003) Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 139:1325–1332
Author information
Authors and Affiliations
Corresponding author
Additional information
None of the authors has any proprietary financial interest in the results described herein. No specific public or private financial support was received for this study.
Rights and permissions
About this article
Cite this article
Choontanom, R., Thanos, S., Busse, H. et al. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol 245, 1217–1220 (2007). https://doi.org/10.1007/s00417-007-0561-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-007-0561-1